In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (DMT) approved for the treatment of primary-progressive multiple sclerosis (PP-MS). Although the drug’s efficacy appears more modest in this population than in patients with relapsing forms of MS, the combination of proven clinical benefits and a positive safety profile (to date) yields a highly compelling product for a deeply underserved population. Even so, questions remain about exactly how it will fit into the progressive MS treatment algorithm. DRG’s launch tracking series will examine how the perception and performance of Ocrevus has evolved through Year 1 with an MS prescriber base that has hitherto struggled to treat PP-MS.
- What is the awareness of, familiarity with, and perception of Ocrevus among U.S. neurologists?
- For which PP-MS patients are neurologists prescribing Ocrevus, what are the reasons for prescribing, and how satisfied are they with Ocrevus?
- What promotional messages and activities are Genentech/Roche using to support the Ocrevus launch in PP-MS?
- How does the trial and adoption of Ocrevus in PP-MS compare to the trial and adoption of Ocrevus and other recently launched products in the saturated relapsing MS market? How do adopters and nonadopters in PP-MS compare across key metrics?
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Markets covered: United States.
Primary research: Survey of approximately 75 U.S. neurologists.
Key metrics included:
- Unaided and aided awareness of Ocrevus.
- Familiarity with and impressions of Ocrevus.
- Prescriber and nonprescriber profiles.
- Willingness to prescribe Ocrevus.
- Performance of Ocrevus on key attributes.
- Sales representative frequency, reach, and satisfaction.
- Benchmarking against previously launched MS agents.
- Multiple Sclerosis - Emerging Therapies - Ocrevus PP-MS Launch Tracking Wave 3 (US)
Author(s): Sarah Soucy
Sarah Soucy, M.S., is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis.
Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her B.S. in Animal Science with a Bioscience and Technology option and her M.S. in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism